Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Toremifene Citrate Fareston 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Trametinib Mekinist 0.5 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
N/A Ziftomenib Komzifti 200mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2025 In Use
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Pomalidomide Pomalyst 4 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.